Organisation paid for research Program year 2023 Source: CMS Open Payments

Arthritis Group PC

Neither a doctor nor a teaching hospital

Research payments

$231,533

48 payments

Through program year 2023, Arthritis Group PC is reported as receiving $231,533 in research payments, across 48 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$56,224	9
2022	Research	$75,562	6
2021	Research	$17,236	7
2020	Research	$34,210	13
2019	Research	$48,301	13

Breakdown

Who paid Research payments · program years 2019–2023

AbbVie, Inc. $131,786 15 payments
Gilead Sciences, Inc. $99,747 33 payments

Studies the money was for Research payments · program years 2019–2023

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) $131,786 15 payments
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $7,018 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $5,790 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $5,614 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $4,344 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $4,344 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $3,954 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $3,930 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $3,825 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $3,788 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.